OncoMatch/Clinical Trials/NCT06547203
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
Is NCT06547203 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Cetuximab and Toripalimab for colorectal cancer metastatic.
Treatment: Cetuximab · Toripalimab · Irinotecan — The objective of this clinical trial is to evaluate the efficacy and safety of cetuximab combined with PD-1 inhibitor and irinotecan in negative ultraselection RAS/BRAF wild-type refractory right-sided metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Colorectal Cancer
Biomarker criteria
Required: KRAS wild-type
Histologically tested as RAS/BRAF V600E wild-type
Required: NRAS wild-type
Histologically tested as RAS/BRAF V600E wild-type
Required: BRAF V600E wild-type
Histologically tested as RAS/BRAF V600E wild-type
Required: PIK3CA wild-type
negative ultraselected for mutations including: RAS/BRAF V600E/PIK3CA/PTEN/EGFR (ECD), HER2 and MET amplification, and ALK/RET/NTRK1 gene fusions
Required: PTEN wild-type
negative ultraselected for mutations including: RAS/BRAF V600E/PIK3CA/PTEN/EGFR (ECD), HER2 and MET amplification, and ALK/RET/NTRK1 gene fusions
Required: EGFR extracellular domain wild-type
negative ultraselected for mutations including: RAS/BRAF V600E/PIK3CA/PTEN/EGFR (ECD), HER2 and MET amplification, and ALK/RET/NTRK1 gene fusions
Required: HER2 (ERBB2) amplification wild-type
negative ultraselected for mutations including: RAS/BRAF V600E/PIK3CA/PTEN/EGFR (ECD), HER2 and MET amplification, and ALK/RET/NTRK1 gene fusions
Required: MET amplification wild-type
negative ultraselected for mutations including: RAS/BRAF V600E/PIK3CA/PTEN/EGFR (ECD), HER2 and MET amplification, and ALK/RET/NTRK1 gene fusions
Required: ALK fusion wild-type
negative ultraselected for mutations including: RAS/BRAF V600E/PIK3CA/PTEN/EGFR (ECD), HER2 and MET amplification, and ALK/RET/NTRK1 gene fusions
Required: RET fusion wild-type
negative ultraselected for mutations including: RAS/BRAF V600E/PIK3CA/PTEN/EGFR (ECD), HER2 and MET amplification, and ALK/RET/NTRK1 gene fusions
Required: NTRK1 fusion wild-type
negative ultraselected for mutations including: RAS/BRAF V600E/PIK3CA/PTEN/EGFR (ECD), HER2 and MET amplification, and ALK/RET/NTRK1 gene fusions
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: VEGF inhibitor (bevacizumab)
Patients who have progressed after previous treatments including bevacizumab, irinotecan, oxaliplatin, and 5-fluorouracil
Must have received: topoisomerase inhibitor (irinotecan)
Patients who have progressed after previous treatments including bevacizumab, irinotecan, oxaliplatin, and 5-fluorouracil, with tumor progression occurring during or within 3 months after irinotecan treatment
Must have received: platinum-based chemotherapy (oxaliplatin)
Patients who have progressed after previous treatments including bevacizumab, irinotecan, oxaliplatin, and 5-fluorouracil
Must have received: antimetabolite (5-fluorouracil)
Patients who have progressed after previous treatments including bevacizumab, irinotecan, oxaliplatin, and 5-fluorouracil
Cannot have received: EGFR-targeted therapy
No prior treatment with anti-EGFR
Cannot have received: anti-PD-1 therapy
No prior treatment with ... PD-1 antibodies
Lab requirements
Blood counts
platelets >90×10^9/L; white blood cells >3×10^9/L; neutrophils >1.5×10^9/L; albumin ≥35 g/L
Kidney function
Serum creatinine less than ULN, or calculated creatinine clearance >50 ml/min (using the Cockcroft-Gault formula)
Liver function
Serum bilirubin ≤1.5 times the upper limit of normal (ULN), transaminases ≤5 times ULN, Liver function classified as Child-Pugh grade A
Normal hematological function (platelets >90×10^9/L; white blood cells >3×10^9/L; neutrophils >1.5×10^9/L). Serum bilirubin ≤1.5 times the upper limit of normal (ULN), transaminases ≤5 times ULN. Liver function classified as Child-Pugh grade A. Serum creatinine less than ULN, or calculated creatinine clearance >50 ml/min (using the Cockcroft-Gault formula). Albumin ≥35 g/L.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06547203 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EGFR-targeted therapy, anti-PD-1 therapy disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS wild-type is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS wild-type is a required biomarker for enrollment.
Does this trial require BRAF?
Yes, BRAF V600E wild-type is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages